AKT1 and prostate carcinoma: Other HT derivatives, but not HT-C6, have been described to target key signaling pathways in prostate cancer cells, such as MAPK, AKT, JAK/STAT, TFGβ and NF-κB pathways, although this effect was assessed in longer treatment conditions (24 h), and the impairment of NF-κB nuclear translocation was not evaluated [28].